Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning

Background and objectives: Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed the risk factors (RFs) for the development of FN and SBI in the first 100 d post‐transplant in 195 consecutive adu...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of haematology Vol. 88; no. 1; pp. 46 - 51
Main Authors Facchini, Luca, Martino, Rodrigo, Ferrari, Angela, Piñana, José L., Valcárcel, David, Barba, Pere, Granell, Miguel, Delgado, Julio, Briones, Javier, Sureda, Anna, Brunet, Salut, Sierra, Jorge
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.01.2012
Subjects
Online AccessGet full text
ISSN0902-4441
1600-0609
1600-0609
DOI10.1111/j.1600-0609.2011.01724.x

Cover

Abstract Background and objectives: Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed the risk factors (RFs) for the development of FN and SBI in the first 100 d post‐transplant in 195 consecutive adult recipients of a reduced‐intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC‐allo). Materials and methods: The RIC regimens consisted of fludarabine plus melphalan (62%) or busulphan (38%) (FluMel or FluBu). SBIs include pneumonia, urinary tract infections, and bacteremia. Results: FN occurred in 141 patients (72%), always in the first 30 d post‐allo‐RIC. However, a SBI occurred in only 27 patients (14%) during this early post‐transplant period (<day +30), while 29 evaluable patients (15%) developed a SBI in the intermediate post‐transplant period (days +31 to +100). In multivariate analysis, RFs for the development of FN included onset of neutropenia before day +5 after allo‐RIC (P < 0.02) and NCI CTC grade III–IV mucosal damage in the first 10 d post‐transplantation (P = 0.03). RFs identified to SBI by multivariate analysis included corticosteroid therapy before day +100 (P < 0.01), mycophenolate mofetil‐based graft‐versus‐host disease (GVHD) prophylaxis (P < 0.01), and previous SBI before day +30 (P < 0.01). The rate of SBI from day +30 to +100 varied according to the number of RFs; thus, the rate of SBI was 1% in patients without any RF, 17% in patients with one RF, 29% with one RFs, and 53% in those with all three RFs. Conclusions: After an RIC‐allo, FN and early SBI occurred mostly in patients with severe mucositis and early‐onset neutropenia, while postengraftment high‐dose steroid therapy for acute GVHD was the major RF.
AbstractList Background and objectives: Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed the risk factors (RFs) for the development of FN and SBI in the first 100d post-transplant in 195 consecutive adult recipients of a reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC-allo). Materials and methods: The RIC regimens consisted of fludarabine plus melphalan (62%) or busulphan (38%) (FluMel or FluBu). SBIs include pneumonia, urinary tract infections, and bacteremia. Results: FN occurred in 141 patients (72%), always in the first 30d post-allo-RIC. However, a SBI occurred in only 27 patients (14%) during this early post-transplant period (
Background and objectives : Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed the risk factors (RFs) for the development of FN and SBI in the first 100 d post‐transplant in 195 consecutive adult recipients of a reduced‐intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC‐allo). Materials and methods : The RIC regimens consisted of fludarabine plus melphalan (62%) or busulphan (38%) (FluMel or FluBu). SBIs include pneumonia, urinary tract infections, and bacteremia. Results : FN occurred in 141 patients (72%), always in the first 30 d post‐allo‐RIC. However, a SBI occurred in only 27 patients (14%) during this early post‐transplant period (<day +30), while 29 evaluable patients (15%) developed a SBI in the intermediate post‐transplant period (days +31 to +100). In multivariate analysis, RFs for the development of FN included onset of neutropenia before day +5 after allo‐RIC ( P  < 0.02) and NCI CTC grade III–IV mucosal damage in the first 10 d post‐transplantation ( P  = 0.03). RFs identified to SBI by multivariate analysis included corticosteroid therapy before day +100 ( P  < 0.01), mycophenolate mofetil‐based graft‐versus‐host disease (GVHD) prophylaxis ( P  < 0.01), and previous SBI before day +30 ( P  < 0.01). The rate of SBI from day +30 to +100 varied according to the number of RFs; thus, the rate of SBI was 1% in patients without any RF, 17% in patients with one RF, 29% with one RFs, and 53% in those with all three RFs. Conclusions : After an RIC‐allo, FN and early SBI occurred mostly in patients with severe mucositis and early‐onset neutropenia, while postengraftment high‐dose steroid therapy for acute GVHD was the major RF.
Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed the risk factors (RFs) for the development of FN and SBI in the first 100d post-transplant in 195 consecutive adult recipients of a reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC-allo). The RIC regimens consisted of fludarabine plus melphalan (62%) or busulphan (38%) (FluMel or FluBu). SBIs include pneumonia, urinary tract infections, and bacteremia. FN occurred in 141 patients (72%), always in the first 30d post-allo-RIC. However, a SBI occurred in only 27 patients (14%) during this early post-transplant period (<day +30), while 29 evaluable patients (15%) developed a SBI in the intermediate post-transplant period (days +31 to +100). In multivariate analysis, RFs for the development of FN included onset of neutropenia before day +5 after allo-RIC (P<0.02) and NCI CTC grade III-IV mucosal damage in the first 10d post-transplantation (P=0.03). RFs identified to SBI by multivariate analysis included corticosteroid therapy before day +100 (P<0.01), mycophenolate mofetil-based graft-versus-host disease (GVHD) prophylaxis (P<0.01), and previous SBI before day +30 (P<0.01). The rate of SBI from day +30 to +100 varied according to the number of RFs; thus, the rate of SBI was 1% in patients without any RF, 17% in patients with one RF, 29% with one RFs, and 53% in those with all three RFs. After an RIC-allo, FN and early SBI occurred mostly in patients with severe mucositis and early-onset neutropenia, while postengraftment high-dose steroid therapy for acute GVHD was the major RF.
Background and objectives: Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed the risk factors (RFs) for the development of FN and SBI in the first 100 d post‐transplant in 195 consecutive adult recipients of a reduced‐intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC‐allo). Materials and methods: The RIC regimens consisted of fludarabine plus melphalan (62%) or busulphan (38%) (FluMel or FluBu). SBIs include pneumonia, urinary tract infections, and bacteremia. Results: FN occurred in 141 patients (72%), always in the first 30 d post‐allo‐RIC. However, a SBI occurred in only 27 patients (14%) during this early post‐transplant period (<day +30), while 29 evaluable patients (15%) developed a SBI in the intermediate post‐transplant period (days +31 to +100). In multivariate analysis, RFs for the development of FN included onset of neutropenia before day +5 after allo‐RIC (P < 0.02) and NCI CTC grade III–IV mucosal damage in the first 10 d post‐transplantation (P = 0.03). RFs identified to SBI by multivariate analysis included corticosteroid therapy before day +100 (P < 0.01), mycophenolate mofetil‐based graft‐versus‐host disease (GVHD) prophylaxis (P < 0.01), and previous SBI before day +30 (P < 0.01). The rate of SBI from day +30 to +100 varied according to the number of RFs; thus, the rate of SBI was 1% in patients without any RF, 17% in patients with one RF, 29% with one RFs, and 53% in those with all three RFs. Conclusions: After an RIC‐allo, FN and early SBI occurred mostly in patients with severe mucositis and early‐onset neutropenia, while postengraftment high‐dose steroid therapy for acute GVHD was the major RF.
Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed the risk factors (RFs) for the development of FN and SBI in the first 100d post-transplant in 195 consecutive adult recipients of a reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC-allo).BACKGROUND AND OBJECTIVESWhether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed the risk factors (RFs) for the development of FN and SBI in the first 100d post-transplant in 195 consecutive adult recipients of a reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC-allo).The RIC regimens consisted of fludarabine plus melphalan (62%) or busulphan (38%) (FluMel or FluBu). SBIs include pneumonia, urinary tract infections, and bacteremia.MATERIALS AND METHODSThe RIC regimens consisted of fludarabine plus melphalan (62%) or busulphan (38%) (FluMel or FluBu). SBIs include pneumonia, urinary tract infections, and bacteremia.FN occurred in 141 patients (72%), always in the first 30d post-allo-RIC. However, a SBI occurred in only 27 patients (14%) during this early post-transplant period (<day +30), while 29 evaluable patients (15%) developed a SBI in the intermediate post-transplant period (days +31 to +100). In multivariate analysis, RFs for the development of FN included onset of neutropenia before day +5 after allo-RIC (P<0.02) and NCI CTC grade III-IV mucosal damage in the first 10d post-transplantation (P=0.03). RFs identified to SBI by multivariate analysis included corticosteroid therapy before day +100 (P<0.01), mycophenolate mofetil-based graft-versus-host disease (GVHD) prophylaxis (P<0.01), and previous SBI before day +30 (P<0.01). The rate of SBI from day +30 to +100 varied according to the number of RFs; thus, the rate of SBI was 1% in patients without any RF, 17% in patients with one RF, 29% with one RFs, and 53% in those with all three RFs.RESULTSFN occurred in 141 patients (72%), always in the first 30d post-allo-RIC. However, a SBI occurred in only 27 patients (14%) during this early post-transplant period (<day +30), while 29 evaluable patients (15%) developed a SBI in the intermediate post-transplant period (days +31 to +100). In multivariate analysis, RFs for the development of FN included onset of neutropenia before day +5 after allo-RIC (P<0.02) and NCI CTC grade III-IV mucosal damage in the first 10d post-transplantation (P=0.03). RFs identified to SBI by multivariate analysis included corticosteroid therapy before day +100 (P<0.01), mycophenolate mofetil-based graft-versus-host disease (GVHD) prophylaxis (P<0.01), and previous SBI before day +30 (P<0.01). The rate of SBI from day +30 to +100 varied according to the number of RFs; thus, the rate of SBI was 1% in patients without any RF, 17% in patients with one RF, 29% with one RFs, and 53% in those with all three RFs.After an RIC-allo, FN and early SBI occurred mostly in patients with severe mucositis and early-onset neutropenia, while postengraftment high-dose steroid therapy for acute GVHD was the major RF.CONCLUSIONSAfter an RIC-allo, FN and early SBI occurred mostly in patients with severe mucositis and early-onset neutropenia, while postengraftment high-dose steroid therapy for acute GVHD was the major RF.
Author Facchini, Luca
Valcárcel, David
Sierra, Jorge
Granell, Miguel
Briones, Javier
Martino, Rodrigo
Delgado, Julio
Ferrari, Angela
Sureda, Anna
Brunet, Salut
Piñana, José L.
Barba, Pere
Author_xml – sequence: 1
  givenname: Luca
  surname: Facchini
  fullname: Facchini, Luca
  organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
– sequence: 2
  givenname: Rodrigo
  surname: Martino
  fullname: Martino, Rodrigo
  organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
– sequence: 3
  givenname: Angela
  surname: Ferrari
  fullname: Ferrari, Angela
  organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
– sequence: 4
  givenname: José L.
  surname: Piñana
  fullname: Piñana, José L.
  organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
– sequence: 5
  givenname: David
  surname: Valcárcel
  fullname: Valcárcel, David
  organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
– sequence: 6
  givenname: Pere
  surname: Barba
  fullname: Barba, Pere
  organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
– sequence: 7
  givenname: Miguel
  surname: Granell
  fullname: Granell, Miguel
  organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
– sequence: 8
  givenname: Julio
  surname: Delgado
  fullname: Delgado, Julio
  organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
– sequence: 9
  givenname: Javier
  surname: Briones
  fullname: Briones, Javier
  organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
– sequence: 10
  givenname: Anna
  surname: Sureda
  fullname: Sureda, Anna
  organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
– sequence: 11
  givenname: Salut
  surname: Brunet
  fullname: Brunet, Salut
  organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
– sequence: 12
  givenname: Jorge
  surname: Sierra
  fullname: Sierra, Jorge
  organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22023368$$D View this record in MEDLINE/PubMed
BookMark eNqNUk1v1DAQjVAR3Rb-AvINLtmOnQ8nB5BQvxZUAUJFPVqOMy7eZu3FdmD3x_Hf6nTbSnBA9cWjmffejP3mINuzzmKWEQpzms7Rck5rgBxqaOcMKJ0D5aycb55ls8fCXjaDFlheliXdzw5CWAIAayl_ke0zBqwo6maW_TnBa49InCarUblgoglE2p70o5fRODtVLI7RuzVaI4n0SOIPJCu5dJ54E26Ilio6H4hOCZR-2JK1CzGPXtqwHqSNRGPnzYB_C6UmAX9h0uuSAHojB2KsRjW1TUPolCMe-1Fhnxsb0abptkQ525sJYuz1y-y5lkPAV_f3Yfb97PTyeJFffDn_ePzhIlcVVGWOXLelho6XXFJdd2XHW15j0XSFhKpoecUpS2Ffs0KpRsmKS0DZVaAa6GldHGZvdrpr736OGKJYmaBwSI9DNwbRUtqWVQUT8u1_kRQYNCVwzhL09T107FbYi7U3K-m34sGcBHi_AyjvQvCohTLxzpT0tWZIWmLaBrEUk-liMl1M2yDutkFskkDzj8BDjydQ3-2ov5Nv2yfzxOmnxRQlfr7jmxBx88iX_kbUvOCVuPp8Lr6eXF7xb4szAcUty_rffQ
CitedBy_id crossref_primary_10_1007_s00280_020_04118_9
crossref_primary_10_6014_jjsom_19_35
crossref_primary_10_1093_jncimonographs_lgz002
crossref_primary_10_1111_odi_14999
crossref_primary_10_1016_j_ejon_2017_11_006
crossref_primary_10_7889_hct_4_23
crossref_primary_10_4236_aid_2014_42013
crossref_primary_10_1016_j_medcli_2017_09_005
crossref_primary_10_7889_hct_18_013
crossref_primary_10_1007_s00520_024_08776_w
crossref_primary_10_1007_s00520_021_06177_x
crossref_primary_10_1016_j_ccm_2024_10_010
crossref_primary_10_1182_bloodadvances_2019000226
crossref_primary_10_1007_s00520_015_2848_9
crossref_primary_10_3201_eid1910_121048
crossref_primary_10_1016_j_medcle_2018_01_021
crossref_primary_10_1111_tid_12822
crossref_primary_10_1007_s00520_023_07654_1
Cites_doi 10.1038/sj.bmt.1704380
10.1053/bbmt.2002.v8.pm12374456
10.1080/01621459.1958.10501452
10.1093/clinids/23.4.795
10.1086/516925
10.1038/bmt.2008.313
10.1016/j.bbmt.2009.04.004
10.1038/sj.leu.2403105
10.1182/blood-2004-02-0545
10.1182/blood-2009-12-234096
10.1111/j.1399-3062.2004.00075.x
10.1016/j.bbmt.2005.09.004
10.1056/NEJM199103073241005
10.1038/sj.bmt.1701246
10.1016/j.bbmt.2009.07.006
10.1097/01.cco.0000357474.66035.9b
10.1097/01.qco.0000172699.90525.80
10.1038/sj.bmt.1701614
10.1038/sj.bmt.1703643
10.1038/bmt.2009.362
10.1038/bmt.2008.10
10.1016/S0301-472X(03)00201-7
10.1080/10245330310001612125
10.1016/j.bbmt.2003.09.006
10.1038/sj.bmt.1703180
10.1038/sj.bmt.1703150
10.1016/j.bbmt.2007.07.007
10.1038/sj.bmt.1703118
10.1016/S1083-8791(03)00100-9
10.1172/JCI107880
ContentType Journal Article
Copyright 2011 John Wiley & Sons A/S
2011 John Wiley & Sons A/S.
Copyright_xml – notice: 2011 John Wiley & Sons A/S
– notice: 2011 John Wiley & Sons A/S.
DBID BSCLL
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7T5
7T7
8FD
C1K
FR3
H94
P64
7X8
DOI 10.1111/j.1600-0609.2011.01724.x
DatabaseName Istex
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Technology Research Database
Bacteriology Abstracts (Microbiology B)
AIDS and Cancer Research Abstracts
Immunology Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Technology Research Database
CrossRef
MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1600-0609
EndPage 51
ExternalDocumentID 22023368
10_1111_j_1600_0609_2011_01724_x
EJH1724
ark_67375_WNG_PDTW7RHF_0
Genre article
Clinical Trial
Journal Article
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
29G
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAKAS
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AAQQT
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
AEFGJ
AEGXH
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFEBI
AFFPM
AFGKR
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AHEFC
AIACR
AIAGR
AIDQK
AIDYY
AIQQE
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EAS
EBC
EBD
EBS
EGARE
EJD
EMB
EMK
EMOBN
EPT
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
X7M
XG1
Y6R
YFH
YUY
ZCG
ZGI
ZXP
ZZTAW
~IA
~WT
AAHHS
ACCFJ
ADZOD
AEEZP
AEQDE
AEUQT
AFPWT
AIWBW
AJBDE
WRC
WUP
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7T5
7T7
8FD
C1K
FR3
H94
P64
7X8
ID FETCH-LOGICAL-c5054-e7f94f0b747a1f6b4b7976e38b3a0539757123a0d623cc8ca57a0eab50c80d163
IEDL.DBID DR2
ISSN 0902-4441
1600-0609
IngestDate Thu Sep 04 19:55:33 EDT 2025
Tue Oct 07 09:44:45 EDT 2025
Mon Jul 21 05:57:05 EDT 2025
Wed Oct 01 05:11:27 EDT 2025
Thu Apr 24 23:00:57 EDT 2025
Wed Jan 22 16:16:32 EST 2025
Sun Sep 21 06:26:07 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2011 John Wiley & Sons A/S.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5054-e7f94f0b747a1f6b4b7976e38b3a0539757123a0d623cc8ca57a0eab50c80d163
Notes ArticleID:EJH1724
istex:5228D736CDDEB513AF862E26E645989FF3B955DE
ark:/67375/WNG-PDTW7RHF-0
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
PMID 22023368
PQID 1020840772
PQPubID 23462
PageCount 6
ParticipantIDs proquest_miscellaneous_911945506
proquest_miscellaneous_1020840772
pubmed_primary_22023368
crossref_citationtrail_10_1111_j_1600_0609_2011_01724_x
crossref_primary_10_1111_j_1600_0609_2011_01724_x
wiley_primary_10_1111_j_1600_0609_2011_01724_x_EJH1724
istex_primary_ark_67375_WNG_PDTW7RHF_0
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate January 2012
PublicationDateYYYYMMDD 2012-01-01
PublicationDate_xml – month: 01
  year: 2012
  text: January 2012
PublicationDecade 2010
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: England
PublicationTitle European journal of haematology
PublicationTitleAlternate Eur J Haematol
PublicationYear 2012
Publisher Blackwell Publishing Ltd
Publisher_xml – name: Blackwell Publishing Ltd
References Rinehart JJ, Balcerzak SP, Sogane AL, et al. Effects of corticosteroids on human monocytes function. J Clin Invest 1974;54:1337-43.
Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996;23:795-805.
Van Kraaij MG, Verdonck LF, Rozenberg-Arska M, Dekker AW. Early infections in adults undergoing matched related and matched unrelated/mismatched donor stem cell transplantation: a comparison of incidence. Bone Marrow Transplant 2002;30:303-9.
Piñana JL, Valcárcel D, Fernández Avilés F, et al. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplant 2010;45:119-1456.
Sabry W, Le Blanc R, Labbe' AC, et al. Graft versus host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biol Blood Marrow Transplant 2009;15:919-29.
Hori A, Kami M, Kim S-W, et al. Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation. Biol Blood Marrow Transplant 2004;10:65-72.
Mothy M, Jacot W, Faucher C, et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003;17:2168-77.
Robin M, Porcher R, De Castro Araujo R, et al. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biol Bone Marrow Transplant 2007;13:1304-12.
Daly A, McAfee S, Colby C, et al. Nonmyeloablative bone marrow transplantation: infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant 2003;9:373-82.
Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft- versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56.
Bachanova V, Brunstein CG, Burns LJ, et al. Lower infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. Bone Marrow Transplant 2009;43:237-44.
Maris M, Boeckh M, Storer B, et al. Immunologic recovery after hematopoietic stem cell transplantation with nonmyeloablative conditioning. Exp Hematol 2003;31:941-52.
Ferrara JL, Deeg HJ. Graft versus host disease. N Engl J Med 1991;324:667-74.
Kruger W, Russmann B, Kroger N, et al. Early infections in patients undergoing bone marrow or blood stem transplantation: a 7 year single center investigation of 409 cases. Bone Marrow Transplant 1999;23:589-97.
Kornblit B, Masmas T, Madsen HO, et al. Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants. Bone Marrow Transplant 2008;41:851-9.
Martino R, Caballero MD, Canals C, et al. Reduced intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem transplantation. Bone Marrow Transplant 2001;28:341-7.
Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004;104:961-8.
Brown JM. The influence of the conditions of hematopoietic cell transplantation on infectious complications. Curr Opin Infect Dis 2005;18:346-51.
Seggenwiss R, Einsele H. Immune reconstitution alter allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010;115:3861-8.
Meijer E, Dekker AW, Lokhorst HM, et al. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transpl Infect Dis 2004;6:171-1788.
Morecki S, Gelfand Y, Nagler A, et al. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Bone Marrow Transplant 2001;28:243-9.
Yuen KY, Woo PC, Hui CH, Luk WK, Chen FE, Lie AK, Liang R. Unique risk factors for bacteriaemia in allogeneic bone marrow transplant recipients before and after engraftment. Bone Marrow Transplant 1998;21:1137-43.
Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002;8:512-20.
Busca A, Lovisone E, Aliberti S, et al. Immune reconstitution and early infectious complications following nonmyeloablative hematopoietic stem cell transplantation. Hematology 2003;8:303-11.
McCann S, Byrne JL, Rovira M, et al. Outbreaks of infectious disease in stem cell transplant units: a silent cause of death for patients and transplant programmes. Bone Marrow Transplant 2004;33:519-29.
Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-8.
Hamadani M, Blum W, Phillips G, et al. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2009;15:1422-30.
Mossad SB, Avery RK, Longworth DL, et al. Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001;28:491-5.
Murphy M, Brown AE, Sepkowitz KA, et al. Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer. Is it justified? (letter). Clin Infect Dis 1997;25:346-8.
Valcárcel D, Martino R, Piñana JL, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning for acute myeloid leukaemia: impact of chronic graft-versus-host disease. Curr Opin Oncol 2009;21(Suppl 1):S35-7.
2004; 104
2009; 43
2009; 21
1974; 54
2002; 30
1995; 15
1997; 25
2002; 8
1958; 53
1999; 23
2004; 6
2003; 17
2001; 28
1998; 21
2003; 31
2007; 13
2004; 10
2010; 45
2004; 33
2010; 115
2003; 8
2003; 9
2008; 41
2005; 18
1991; 324
2005; 11
2009; 15
1996; 23
e_1_2_5_26_2
e_1_2_5_27_2
e_1_2_5_24_2
e_1_2_5_25_2
e_1_2_5_22_2
e_1_2_5_23_2
e_1_2_5_20_2
e_1_2_5_21_2
e_1_2_5_28_2
e_1_2_5_29_2
e_1_2_5_14_2
e_1_2_5_13_2
e_1_2_5_9_2
e_1_2_5_8_2
e_1_2_5_15_2
e_1_2_5_7_2
e_1_2_5_10_2
e_1_2_5_6_2
e_1_2_5_5_2
e_1_2_5_12_2
e_1_2_5_31_2
e_1_2_5_4_2
e_1_2_5_11_2
e_1_2_5_32_2
e_1_2_5_3_2
e_1_2_5_2_2
e_1_2_5_18_2
e_1_2_5_17_2
e_1_2_5_19_2
e_1_2_5_30_2
Przepiorka D (e_1_2_5_16_2) 1995; 15
References_xml – reference: Rinehart JJ, Balcerzak SP, Sogane AL, et al. Effects of corticosteroids on human monocytes function. J Clin Invest 1974;54:1337-43.
– reference: Meijer E, Dekker AW, Lokhorst HM, et al. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transpl Infect Dis 2004;6:171-1788.
– reference: Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004;104:961-8.
– reference: McCann S, Byrne JL, Rovira M, et al. Outbreaks of infectious disease in stem cell transplant units: a silent cause of death for patients and transplant programmes. Bone Marrow Transplant 2004;33:519-29.
– reference: Murphy M, Brown AE, Sepkowitz KA, et al. Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer. Is it justified? (letter). Clin Infect Dis 1997;25:346-8.
– reference: Kornblit B, Masmas T, Madsen HO, et al. Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants. Bone Marrow Transplant 2008;41:851-9.
– reference: Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
– reference: Valcárcel D, Martino R, Piñana JL, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning for acute myeloid leukaemia: impact of chronic graft-versus-host disease. Curr Opin Oncol 2009;21(Suppl 1):S35-7.
– reference: Busca A, Lovisone E, Aliberti S, et al. Immune reconstitution and early infectious complications following nonmyeloablative hematopoietic stem cell transplantation. Hematology 2003;8:303-11.
– reference: Sabry W, Le Blanc R, Labbe' AC, et al. Graft versus host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biol Blood Marrow Transplant 2009;15:919-29.
– reference: Robin M, Porcher R, De Castro Araujo R, et al. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biol Bone Marrow Transplant 2007;13:1304-12.
– reference: Seggenwiss R, Einsele H. Immune reconstitution alter allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010;115:3861-8.
– reference: Hamadani M, Blum W, Phillips G, et al. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2009;15:1422-30.
– reference: Ferrara JL, Deeg HJ. Graft versus host disease. N Engl J Med 1991;324:667-74.
– reference: Kruger W, Russmann B, Kroger N, et al. Early infections in patients undergoing bone marrow or blood stem transplantation: a 7 year single center investigation of 409 cases. Bone Marrow Transplant 1999;23:589-97.
– reference: Brown JM. The influence of the conditions of hematopoietic cell transplantation on infectious complications. Curr Opin Infect Dis 2005;18:346-51.
– reference: Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft- versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56.
– reference: Mothy M, Jacot W, Faucher C, et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003;17:2168-77.
– reference: Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-8.
– reference: Bachanova V, Brunstein CG, Burns LJ, et al. Lower infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. Bone Marrow Transplant 2009;43:237-44.
– reference: Daly A, McAfee S, Colby C, et al. Nonmyeloablative bone marrow transplantation: infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant 2003;9:373-82.
– reference: Piñana JL, Valcárcel D, Fernández Avilés F, et al. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplant 2010;45:119-1456.
– reference: Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996;23:795-805.
– reference: Martino R, Caballero MD, Canals C, et al. Reduced intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem transplantation. Bone Marrow Transplant 2001;28:341-7.
– reference: Maris M, Boeckh M, Storer B, et al. Immunologic recovery after hematopoietic stem cell transplantation with nonmyeloablative conditioning. Exp Hematol 2003;31:941-52.
– reference: Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002;8:512-20.
– reference: Morecki S, Gelfand Y, Nagler A, et al. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Bone Marrow Transplant 2001;28:243-9.
– reference: Hori A, Kami M, Kim S-W, et al. Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation. Biol Blood Marrow Transplant 2004;10:65-72.
– reference: Mossad SB, Avery RK, Longworth DL, et al. Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001;28:491-5.
– reference: Van Kraaij MG, Verdonck LF, Rozenberg-Arska M, Dekker AW. Early infections in adults undergoing matched related and matched unrelated/mismatched donor stem cell transplantation: a comparison of incidence. Bone Marrow Transplant 2002;30:303-9.
– reference: Yuen KY, Woo PC, Hui CH, Luk WK, Chen FE, Lie AK, Liang R. Unique risk factors for bacteriaemia in allogeneic bone marrow transplant recipients before and after engraftment. Bone Marrow Transplant 1998;21:1137-43.
– volume: 53
  start-page: 457
  year: 1958
  end-page: 81
  article-title: Non‐parametric estimation from incomplete observations
  publication-title: J Am Stat Assoc
– volume: 13
  start-page: 1304
  year: 2007
  end-page: 12
  article-title: Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor
  publication-title: Biol Bone Marrow Transplant
– volume: 6
  start-page: 171
  year: 2004
  end-page: 1788
  article-title: Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation
  publication-title: Transpl Infect Dis
– volume: 45
  start-page: 119
  year: 2010
  end-page: 1456
  article-title: MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced‐intensity conditioning PBSCT from HLA‐identical siblings
  publication-title: Bone Marrow Transplant
– volume: 30
  start-page: 303
  year: 2002
  end-page: 9
  article-title: Early infections in adults undergoing matched related and matched unrelated/mismatched donor stem cell transplantation: a comparison of incidence
  publication-title: Bone Marrow Transplant
– volume: 115
  start-page: 3861
  year: 2010
  end-page: 8
  article-title: Immune reconstitution alter allogeneic transplantation and expanding options for immunomodulation: an update
  publication-title: Blood
– volume: 43
  start-page: 237
  year: 2009
  end-page: 44
  article-title: Lower infections and lower infection‐related mortality following non‐myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma
  publication-title: Bone Marrow Transplant
– volume: 28
  start-page: 491
  year: 2001
  end-page: 5
  article-title: Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation
  publication-title: Bone Marrow Transplant
– volume: 11
  start-page: 945
  year: 2005
  end-page: 56
  article-title: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐ versus‐host disease: I. Diagnosis and staging working group report
  publication-title: Biol Blood Marrow Transplant
– volume: 25
  start-page: 346
  year: 1997
  end-page: 8
  article-title: Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer. Is it justified? (letter)
  publication-title: Clin Infect Dis
– volume: 8
  start-page: 303
  year: 2003
  end-page: 11
  article-title: Immune reconstitution and early infectious complications following nonmyeloablative hematopoietic stem cell transplantation
  publication-title: Hematology
– volume: 23
  start-page: 589
  year: 1999
  end-page: 97
  article-title: Early infections in patients undergoing bone marrow or blood stem transplantation: a 7 year single center investigation of 409 cases
  publication-title: Bone Marrow Transplant
– volume: 33
  start-page: 519
  year: 2004
  end-page: 29
  article-title: Outbreaks of infectious disease in stem cell transplant units: a silent cause of death for patients and transplant programmes
  publication-title: Bone Marrow Transplant
– volume: 28
  start-page: 243
  year: 2001
  end-page: 9
  article-title: Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen
  publication-title: Bone Marrow Transplant
– volume: 31
  start-page: 941
  year: 2003
  end-page: 52
  article-title: Immunologic recovery after hematopoietic stem cell transplantation with nonmyeloablative conditioning
  publication-title: Exp Hematol
– volume: 54
  start-page: 1337
  year: 1974
  end-page: 43
  article-title: Effects of corticosteroids on human monocytes function
  publication-title: J Clin Invest
– volume: 21
  start-page: 1137
  year: 1998
  end-page: 43
  article-title: Unique risk factors for bacteriaemia in allogeneic bone marrow transplant recipients before and after engraftment
  publication-title: Bone Marrow Transplant
– volume: 18
  start-page: 346
  year: 2005
  end-page: 51
  article-title: The influence of the conditions of hematopoietic cell transplantation on infectious complications
  publication-title: Curr Opin Infect Dis
– volume: 15
  start-page: 1422
  year: 2009
  end-page: 30
  article-title: Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced intensity conditioning allogeneic transplantation for hematologic malignancies
  publication-title: Biol Blood Marrow Transplant
– volume: 17
  start-page: 2168
  year: 2003
  end-page: 77
  article-title: Infectious complications following allogeneic HLA‐identical sibling transplantation with antithymocyte globulin‐based reduced intensity preparative regimen
  publication-title: Leukemia
– volume: 15
  start-page: 919
  year: 2009
  end-page: 29
  article-title: Graft versus host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA‐matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality
  publication-title: Biol Blood Marrow Transplant
– volume: 8
  start-page: 512
  year: 2002
  end-page: 20
  article-title: Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study
  publication-title: Biol Blood Marrow Transplant
– volume: 10
  start-page: 65
  year: 2004
  end-page: 72
  article-title: Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced‐intensity stem cell transplantation
  publication-title: Biol Blood Marrow Transplant
– volume: 21
  start-page: S35
  issue: Suppl 1
  year: 2009
  end-page: 7
  article-title: Allogeneic stem cell transplantation after reduced‐intensity conditioning for acute myeloid leukaemia: impact of chronic graft‐versus‐host disease
  publication-title: Curr Opin Oncol
– volume: 23
  start-page: 795
  year: 1996
  end-page: 805
  article-title: Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta‐analysis
  publication-title: Clin Infect Dis
– volume: 28
  start-page: 341
  year: 2001
  end-page: 7
  article-title: Reduced intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem transplantation
  publication-title: Bone Marrow Transplant
– volume: 15
  start-page: 825
  year: 1995
  end-page: 8
  article-title: 1994 consensus conference on acute GVHD grading
  publication-title: Bone Marrow Transplant
– volume: 9
  start-page: 373
  year: 2003
  end-page: 82
  article-title: Nonmyeloablative bone marrow transplantation: infectious complications in 65 recipients of HLA‐identical and mismatched transplants
  publication-title: Biol Blood Marrow Transplant
– volume: 104
  start-page: 961
  year: 2004
  end-page: 8
  article-title: Comparing morbidity and mortality of HLA matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities
  publication-title: Blood
– volume: 41
  start-page: 851
  year: 2008
  end-page: 9
  article-title: Haematopoietic cell transplantation with non‐myeloablative conditioning in Denmark: disease‐specific outcome, complications and hospitalization requirements of the first 100 transplants
  publication-title: Bone Marrow Transplant
– volume: 324
  start-page: 667
  year: 1991
  end-page: 74
  article-title: Graft versus host disease
  publication-title: N Engl J Med
– ident: e_1_2_5_12_2
  doi: 10.1038/sj.bmt.1704380
– ident: e_1_2_5_6_2
  doi: 10.1053/bbmt.2002.v8.pm12374456
– ident: e_1_2_5_18_2
  doi: 10.1080/01621459.1958.10501452
– ident: e_1_2_5_31_2
  doi: 10.1093/clinids/23.4.795
– ident: e_1_2_5_32_2
  doi: 10.1086/516925
– ident: e_1_2_5_2_2
  doi: 10.1038/bmt.2008.313
– ident: e_1_2_5_29_2
  doi: 10.1016/j.bbmt.2009.04.004
– ident: e_1_2_5_8_2
  doi: 10.1038/sj.leu.2403105
– ident: e_1_2_5_10_2
  doi: 10.1182/blood-2004-02-0545
– ident: e_1_2_5_28_2
  doi: 10.1182/blood-2009-12-234096
– ident: e_1_2_5_5_2
  doi: 10.1111/j.1399-3062.2004.00075.x
– ident: e_1_2_5_17_2
  doi: 10.1016/j.bbmt.2005.09.004
– ident: e_1_2_5_26_2
  doi: 10.1056/NEJM199103073241005
– ident: e_1_2_5_27_2
  doi: 10.1038/sj.bmt.1701246
– ident: e_1_2_5_30_2
  doi: 10.1016/j.bbmt.2009.07.006
– ident: e_1_2_5_15_2
  doi: 10.1097/01.cco.0000357474.66035.9b
– ident: e_1_2_5_22_2
  doi: 10.1097/01.qco.0000172699.90525.80
– ident: e_1_2_5_11_2
  doi: 10.1038/sj.bmt.1701614
– ident: e_1_2_5_13_2
  doi: 10.1038/sj.bmt.1703643
– ident: e_1_2_5_14_2
  doi: 10.1038/bmt.2009.362
– ident: e_1_2_5_23_2
  doi: 10.1038/bmt.2008.10
– ident: e_1_2_5_21_2
  doi: 10.1016/S0301-472X(03)00201-7
– ident: e_1_2_5_20_2
  doi: 10.1080/10245330310001612125
– volume: 15
  start-page: 825
  year: 1995
  ident: e_1_2_5_16_2
  article-title: 1994 consensus conference on acute GVHD grading
  publication-title: Bone Marrow Transplant
– ident: e_1_2_5_3_2
  doi: 10.1016/j.bbmt.2003.09.006
– ident: e_1_2_5_9_2
  doi: 10.1038/sj.bmt.1703180
– ident: e_1_2_5_4_2
  doi: 10.1038/sj.bmt.1703150
– ident: e_1_2_5_24_2
  doi: 10.1016/j.bbmt.2007.07.007
– ident: e_1_2_5_19_2
  doi: 10.1038/sj.bmt.1703118
– ident: e_1_2_5_7_2
  doi: 10.1016/S1083-8791(03)00100-9
– ident: e_1_2_5_25_2
  doi: 10.1172/JCI107880
SSID ssj0002917
Score 2.0532832
Snippet Background and objectives: Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not...
Background and objectives : Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not...
Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed...
SourceID proquest
pubmed
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 46
SubjectTerms Adult
allogeneic hematopoietic stem cell transplantation
Bacteria
Bacterial Infections - epidemiology
Bacterial Infections - etiology
Busulfan - administration & dosage
Busulfan - adverse effects
early post-transplant infections
febrile neutropenia
Female
Graft vs Host Disease - epidemiology
Graft vs Host Disease - prevention & control
Hematopoietic Stem Cell Transplantation
Humans
Immunosuppressive Agents - administration & dosage
Immunosuppressive Agents - adverse effects
intermediate post-transplant infections
Male
Melphalan - administration & dosage
Melphalan - adverse effects
Middle Aged
Mucositis - epidemiology
Mucositis - etiology
Mycophenolic Acid - administration & dosage
Mycophenolic Acid - adverse effects
Mycophenolic Acid - analogs & derivatives
Myeloablative Agonists - administration & dosage
Myeloablative Agonists - adverse effects
Neutropenia - epidemiology
Neutropenia - etiology
reduced-intensity conditioning
Retrospective Studies
Risk Factors
severe bacterial infections
Time Factors
Transplantation Conditioning
Transplantation, Homologous
Title Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning
URI https://api.istex.fr/ark:/67375/WNG-PDTW7RHF-0/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1600-0609.2011.01724.x
https://www.ncbi.nlm.nih.gov/pubmed/22023368
https://www.proquest.com/docview/1020840772
https://www.proquest.com/docview/911945506
Volume 88
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVEBS
  databaseName: Academic Search Ultimate - eBooks
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1600-0609
  dateEnd: 20241028
  omitProxy: true
  ssIdentifier: ssj0002917
  issn: 0902-4441
  databaseCode: ABDBF
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVWIB
  databaseName: Wiley Online Library - Core collection (SURFmarket)
  issn: 0902-4441
  databaseCode: DR2
  dateStart: 19970101
  customDbUrl:
  isFulltext: true
  eissn: 1600-0609
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0002917
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3batwwEBUlgdKXNr27N1QoffPiiyytHkuT7RJIKCEheRO6GdJN7OC1Ie1TP6G_1F_Jl2TG8m7rkkIofTNr67YazZyRRmcIeZcyoXNTprEsXB4zX7jYZNLFuZHMljYD9YCO4t4-nx-x3ZPiZIh_wrswgR9iveGGK6PX17jAtVmOFznHW9E8kQMTJ9hiNkE8mea8964OfjFJZbJPvotRiDEDCDAO6rmxopGl2sQ__fImGDpGtb1Zmj0gi9WAQjTKYtK1ZmK__cH1-H9GvEXuD-iVfgji9pDc8dUjcndvOJ9_TH5ue_DfPa1Leo6h8EiYRHXlqOuCpOGbynctHgFUp5rqxlOAoPRcf6kbinHudMgARAFNU4_0y_SiXrZX33-0PQ_7GYgCLcGThyGMq4JmwMx7qNEECmro6SrWrIJuYDZ02iBVrXdQ3WkI3m-_UlvjuX3YmH5CjmY7hx_n8ZAkIrYA3ljsRSlZmRhwi3RacsOMAITl86nJNSgYKQoBxlknDnCetVOrC6ETr02R2GniAI0-JRtVXfnnhBrv0P0SWkrGkBfHpFy6jEtegCbUPiJiJRDKDgzqmMjjTP3mScEMKZwhhTOk-hlSlxFJ1yUvAovILcq872VuXUA3C4zCE4U63v-kPm8fHouD-UwlEXm7EkoFugEPfHTl624JTWQJOPDgQEWE_uUbMHYSb7bziDwLAr1uMMsA0OV8GhHei-Wtu652duf49OJfC74k9-DnLGx1vSIbbdP51wD-WvOmX9bXhRZOiA
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3bbtQwELVQKwEv3CnhaiTEW1a5OPb6EdEuS-muULVV-2b5Fql0m1RpIhWe-AR-iV_hS5hJsgtBRaoQb5ES3-LxzBl7fIaQVzETOjV5HMrMpSHzmQtNIl2YGslsbhNQD-gozuZ8esB2j7KjPh0Q3oXp-CHWG264Mlp9jQscN6SHq5zjtWgeyZ6KE4wxGwGg3GQc3BZESPu_uKQS2abfxTjEkAEIGIb1XFrTwFZt4m-_uAyIDnFta5gmt8lyNaQuHuVk1NRmZL_8wfb4n8Z8h9zqASx900ncXXLNF_fI9Vl_RH-ffN_24MJ7Wub0FKPhkTOJ6sJR13TChm8K39R4ClAca6orTwGF0lP9qawohrrTPgkQBUBNPTIw07PyvP7x9VvdUrEvQRpoDs48jGFYFTQDlt5DjaZjoYaersLNCugGJkSnFbLVegfVHXfx-_Vnaks8uu_2ph-Qg8nO4u007PNEhBbwGwu9yCXLIwOekY5zbpgRALJ8OjapBh0jRSbAPuvIAdSzdmx1JnTktckiO44cANKHZKMoC_-IUOMdemBCS8kYUuOYmEuXcMkzUIbaB0SsJELZnkQdc3ks1W_OFMyQwhlSOEOqnSF1EZB4XfKsIxK5QpnXrdCtC-jqBAPxRKYO5-_Ux-3FodifTlQUkJcrqVSgHvDMRxe-bM6hiSQCHx58qIDQv3wD9k7i5XYekK1OotcNJglgupSPA8Jbubxy19XO7hSfHv9rwRfkxnQx21N77-cfnpCb8EnS7Xw9JRt11fhngAVr87xd4z8BZnNSqQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3batwwEBUlgdCX3i_uVYXSNy9eW5asx9LNdps2SwgJyZvQzZBkYy-ODWmf-gn9pf5Kv6QztndblxRC6ZvB1s0azZyRRmcIeT1mQicmH4cydUnIfOpCE0sXJkYym9sY1AM6irtzPjtkO8fpcZ8OCO_CdPwQ6w03XBmtvsYF7pcuH65yjteieSR7Kk4wxmwEgHKTpTLD-L7J_i8uqVi26XcxDjFkAAKGYT1X1jSwVZv42y-vAqJDXNsapultslgNqYtHORs1tRnZL3-wPf6nMd8ht3oAS992EneX3PDFPbK12x_R3yffJx5ceE_LnJ5jNDxyJlFdOOqaTtjwTeGbGk8BihNNdeUpoFB6rk_LimKoO-2TAFEA1NQjAzNdlhf1j6_f6paKfQHSQHNw5mEMw6qgGbD0Hmo0HQs19HQVblZANzAhOq2QrdY7qO6ki9-vP1Nb4tF9tzf9gBxOtw_ezcI-T0RoAb-x0Itcsjwy4Bnpcc4NMwJAlk8yk2jQMVKkAuyzjhxAPWszq1OhI69NGtkscgBIH5KNoiz8Y0KNd-iBCS0lY0iNY8ZcuphLnoIy1D4gYiURyvYk6pjLY6F-c6ZghhTOkMIZUu0MqcuAjNcllx2RyDXKvGmFbl1AV2cYiCdSdTR_r_YmB0difzZVUUBeraRSgXrAMx9d-LK5gCbiCHx48KECQv_yDdg7iZfbeUAedRK9bjCOAdMlPAsIb-Xy2l1X2zszfHryrwVfkq29yVR9-jD_-JTchC_ibuPrGdmoq8Y_ByhYmxftEv8JnSBSLQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Degree+of+mucositis+and+duration+of+neutropenia+are+the+major+risk+factors+for+early+post-transplant+febrile+neutropenia+and+severe+bacterial+infections+after+reduced-intensity+conditioning&rft.jtitle=European+journal+of+haematology&rft.au=Facchini%2C+Luca&rft.au=Martino%2C+Rodrigo&rft.au=Ferrari%2C+Angela&rft.au=Pinana%2C+Jose+L&rft.date=2012-01-01&rft.issn=0902-4441&rft.eissn=1600-0609&rft.volume=88&rft.issue=1&rft.spage=46&rft.epage=51&rft_id=info:doi/10.1111%2Fj.1600-0609.2011.01724.x&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0902-4441&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0902-4441&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0902-4441&client=summon